Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products
Halozyme Therapeutics' record-breaking 2024 revenue exceeded $1B, with strong 2025 growth projections led by DARZALEX & VYVGART.
Le Lézard5d
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to ...